EUCTR2019-001807-19-DK进行中（未招募）1 期
An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) - Open RECLAIM-DCP
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 185
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who have completed Study TV50717-CNS-30080 have already met the criteria below:
- •a. Patient has completed week 16 of Study TV50717-CNS-30080.
- •b. Patient weighs at least 12 kg (26 lb) on day 1 of this study.
- •c. Patient is able to swallow TEV-50717 tablet whole.
- •d. Patient and caregiver are willing to adhere to TEV-50717 regimen and comply with all study procedures.
- •e. Patient is in good general health, as indicated by medical and psychiatric history and physical and neurological examination.
- •f. In the investigator’s opinion, the patient and caregiver have the ability to understand the nature of the study and its procedures, and the patient is expected to complete the study as designed.
- •g. For a patient who is a minor, the parent(s)/legally acceptable representative(s) provides written informed consent, and the patient provides assent (in accordance with local regulations). Adult patients provide written informed consent(in accordance with local regulations), and the legally acceptable representative will sign, if needed. In this study, eligible patients with dyskinetic cerebral palsy may have some degree of mental, motor, and/or communication (eg, speech, writing, etc.) limitations or disabilities. The patient may not be able to read the assent/consent form. Some patients may only be able to provide a limited assent/consent (for instance, by verbalizations or gestures). The investigator will determine the suitability of enrolling such patients in this study and will follow the local regulation to obtain the relevant consent/assent.
- •h. A caregiver provides written informed consent after being assigned the role by an adult patient or if this role is delegated by the
- •parent/legally acceptable representative of a patient who is a minor.
- •i. Females who are postmenarchal or =12 years of age may be included only if they have a negative ß-HCG test on day 1 or are sterile.
- •j. Females who are postmenarchal or =12 years of age whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the study (ie, starting at day 1) and for 30 days after last dose of TEV-50717.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 170
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be randomized/enrolled in this study if they meet any of the following criteria:
- •a. Patient has clinically significant depression at screening of this study. Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks before screening or day 1 (whichever comes first) and anticipated to remain stable (dose and frequency) within the study duration.
- •b. Patient has a history of suicidal intent or related behaviors based on medical or psychiatric history or the C-SSRS at screening visit, if performed, or at the day 1 visit, as applicable according to the patient's age: (i) intent to act on suicidal ideation with a specific plan, irrespective of level of ambivalence, at the time of suicidal thought; (ii) suicidal preparatory acts or behaviour.
- •c. Patient has a history of a previous actual, interrupted, or aborted suicide attempt based on medical or psychiatric history or the C-SSRS at screening visit, if performed, or at the day 1 visit, as applicable according to the patient's age.
- •d. Patient has a first-degree relative who has completed suicide.
- •e. Patient has received any of the following concomitant medications within the specified exclusionary windows from screening or day 1 (whichever come first): (a) within 30 days: tetrabenazine or valbenazine; (b) within 21 days: reserpine; (c) within 14 days: levodopa, dopamine agonists, and monoamine oxidase inhibitors.
- •f. Patient has received treatment with stem cells, deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for treatment of abnormal movements or Cere Palsy since the week 15 visit of Study TV50717-CNS-30080, or the patient is not in a stable clinical condition.
- •g. Patient had a surgical procedure since the week 15 visit of Study TV50717-CNS-30080 or is anticipated to have a surgical procedure during the study that, in the opinion of the investigator, makes the patient unsuitable for the study.
- •h. Patient has a severe mental disability or an unstable or serious medical illness (eg, epilepsy) that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study.
- •i. Patient has a QT interval (QTc) corrected for heart rate using Fridericia's formula (QTcF) value >450 msec on 12-lead ECG atscreening or day 1 (whichever comes first) of this study.
- •j. Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, other cardiac arrhythmias, or uncompensated heart failure.
- •k. Patient has evidence of hepatic impairment, as indicated by the following: (a) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× the upper limit of the normal range (ULN) at the week 15 or week 16 visit of Study TV50717-CNS-30080 or screening of this study, as applicable; (b) alkaline phosphatase (ALP) or total bilirubin (Tbil) >2×ULN at the week 15 or week 16 visit of Study TV50717-CNS-30080 or screening of this study, as applicable. Note: Patients with Gilbert's syndrome are eligible to participate if approved by the medical monitor. Note: Patients with abnormalities of AST, ALT, ALP, and Tbil parameters that do not meet the above laboratory criteria for exclusion based on hepatic impairment must be approved for enrollment by the medical monitor.
- •l. Patient has evidence of clinically significant renal impairment, indicated by a serum creatinine >1.5×ULN at the week 15 or week 16 visit
研究者
相似试验
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 21.1Level: PTClassification code 10013916Term: DyskinesiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001807-19-ITTEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC44
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1Level: LLTClassification code 10068804Term: Athetoid cerebral palsySystem Organ Class: 100000004850EUCTR2019-001807-19-GBTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1Level: LLTClassification code 10068804Term: Athetoid cerebral palsySystem Organ Class: 100000004850EUCTR2019-001807-19-PLTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1 Level: LLT Classification code 10068804 Term: Athetoid cerebral palsy System Organ Class: 100000004850EUCTR2019-001807-19-ESTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
不适用
Open label, long-term safety and tolerability extension study of LCQ908 in subjects with Familial Chylomicronemia Syndrome (FCS).Familial Chylomicronemia Syndrome (FCS) (HLP Type I)MedDRA version: 17.1Level: LLTClassification code 10020607Term: HyperchylomicronemiaSystem Organ Class: 100000004861EUCTR2012-000802-32-GBovartis Pharma Services AG42